Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Clinical trial NCT00709618 · TERMINATED

Trial details

NCT number: NCT00709618
Sponsor: GlaxoSmithKline
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Neoplasms, Breast

Start date: 2008-06-01
Primary completion: 2012-05-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.